ArticleScientific reports2025
Diagnostic value of bronchoalveolar lavage fluid metagenomic next-generation sequencing for pulmonary infections in patients with connective tissue disease: A retrospective study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Pulmonary infection is common in connective tissue diseases (CTDs) patients because of immunodeficiency. The basic characteristics of pathogens in this set of patients may differs from immunocompetent patients and largely unclear. We aimed to understand these characteristics by metagenomic next-generation sequencing (mNGS) detection in bronchoalveolar lavage fluid (BALF) from CTDs and explored the primary disease features of this group of patients. Eighty-one CTD patients who were suspected pulmonary infection and received mNGS of BALF as well as conventional microbiologic testing (CMT) were enrolled consecutively. We analysed the types of CTDs, whether accompanied with interstitial lung disease, comparison between performance of mNGS and CMT, and distribution of clinically relevant pathogens, etc. Of the 81 cases, 62 were clinically diagnosed with pulmonary infection. Among all patients, idiopathic inflammatory myopathy accounted for the highest proportion of cases infected, especially anti-MDA5 dermatomyositis and anti-synthetase syndrome. Patients in the pulmonary infection group had been previously treated with higher percentages of anti-rheumatic drugs than those in the non-infection group. The sensitivity of mNGS was higher than that of CMT (80.6% vs. 66.1%). Among the microbes detected by mNGS, the most common bacterial pathogen was Pseudomonas aeruginosa, and the most frequently fungi was Pneumocystis jirovecii. As for the specific pathogens, mNGS had great advantages over CMT in identifying Pneumocystis jirovecii. Idiopathic inflammatory myopathy was the disease most susceptible to pulmonary infections among CTDs. mNGS showed high efficiency for the detection of pathogens that cause pneumonia in BALF from patients with CTDs, especially for Pneumocystis jirovecii.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.